Novel therapeutic targets in depression: minocycline as a candidate treatment.
about
Modulatory Effects of Gut Microbiota on the Central Nervous System: How Gut Could Play a Role in Neuropsychiatric Health and DiseasesGut microbiota in autism and mood disordersBeyond Monoamines-Novel Targets for Treatment-Resistant Depression: A Comprehensive ReviewThe Involvement of TNF-α in Cognitive Dysfunction Associated with Major Depressive Disorder: An Opportunity for Domain Specific TreatmentsGlia in the cytokine-mediated onset of depression: fine tuning the immune responseThe role of glutamate and its receptors in autism and the use of glutamate receptor antagonists in treatment.Glial modulators as potential treatments of psychostimulant abuseIrritable bowel syndrome: a microbiome-gut-brain axis disorder?Minocycline treatment ameliorates interferon-alpha- induced neurogenic defects and depression-like behaviors in mice.Humans as Superorganisms: How Microbes, Viruses, Imprinted Genes, and Other Selfish Entities Shape Our Behavior.On the translocation of bacteria and their lipopolysaccharides between blood and peripheral locations in chronic, inflammatory diseases: the central roles of LPS and LPS-induced cell death.The microbiome and childhood diseases: Focus on brain-gut axis.Minocycline as an adjunct for treatment-resistant depressive symptoms: study protocol for a pilot randomised controlled trial.Crosstalk between endocannabinoid and immune systems: a potential dysregulation in depression?Potential therapeutic approaches for Angelman syndrome.Biotic acts of antibioticsEvidence for TNFα action on excitatory and inhibitory neurotransmission in the central amygdala: a brain site influenced by stressInflammation in Depression and the Potential for Anti-Inflammatory TreatmentMind and body: how the health of the body impacts on neuropsychiatry.Minocycline and celecoxib as adjunctive treatments for bipolar depression: a study protocol for a multicenter factorial design randomized controlled trial.Activation of brain indoleamine 2,3-dioxygenase contributes to epilepsy-associated depressive-like behavior in rats with chronic temporal lobe epilepsy.The integrative management of treatment-resistant depression: a comprehensive review and perspectives.Are medical comorbid conditions of bipolar disorder due to immune dysfunction?Innovative biomarkers in psychiatric disorders: a major clinical challenge in psychiatry.Bipolar Disorder and Immune Dysfunction: Epidemiological Findings, Proposed Pathophysiology and Clinical Implications.Immune-based strategies for mood disorders: facts and challenges.Doxycycline Used for Control of Transgene Expression has its Own Effects on Behaviors and Bcl-xL in the Rat Hippocampus.Therapeutic strategies for treatment of inflammation-related depression.A pilot, open-label, 8-week study evaluating the efficacy, safety and tolerability of adjunctive minocycline for the treatment of bipolar I/II depression.Prevention and reversal of ketamine-induced schizophrenia related behavior by minocycline in mice: Possible involvement of antioxidant and nitrergic pathways.Trained innate immunity: a salient factor in the pathogenesis of neuroimmune psychiatric disorders.Minocycline Attenuates Stress-Induced Behavioral Changes via Its Anti-inflammatory Effects in an Animal Model of Post-traumatic Stress Disorder
P2860
Q26749210-9D76AA87-8164-44BD-877B-1532B24E1135Q26772308-3321DEC6-AB25-4033-9618-A7164BA7ED46Q26782993-9B20FDC4-7184-4800-A838-57F363628DBFQ26783012-CFD6DEAB-C650-436A-9CEE-8E26232AEB22Q26798929-7286EE3A-D0BE-445B-A7DC-58E8D538DAAAQ26998975-A958495A-7C5D-43E7-AA69-9EA63562ACD7Q28307030-35EB7612-DA92-448A-A1D5-815D2188005BQ34366837-6B5C8E2D-4FF3-4397-9956-AAD173F84254Q34667917-3859B28B-8521-426E-866F-87CAFA146FA6Q35692856-CF271C40-D7CE-4646-9CAF-94EC99615747Q35765830-F8C8F66D-36BD-4054-BFF4-49B53139F7F2Q35878852-B7829878-AA28-4726-9240-4CB143EB4376Q36060373-ACB9FF98-D503-4671-994B-B1D32A963E2CQ36789308-2F50F304-7F68-47C7-A0BB-7A378966F0DDQ36992786-07C663B2-7315-406B-B047-5B4AC656F835Q37101851-90F313B0-B023-47F9-A6AD-5FA033896911Q37179039-25ED894A-A42C-4DBD-BD29-0A94D048EDD4Q37310528-74A2F07C-7C12-40EA-8097-9F2C50A5B364Q37399776-47D5816F-E52A-4CC7-9A62-06D988590E37Q37530855-D16CFD5F-4672-4F27-A5A4-1E4082727BC1Q37684964-19150A80-3007-4263-9276-4BF8B20F64C3Q38181363-3F8ACAF1-AE34-485E-AD5E-115D29DD67FDQ38378743-B5F6D6C9-A364-4FBC-B07C-F06D455E5303Q40058836-78D7FD8C-C441-4D48-8EA9-55DE6360EDD5Q47667767-77FAA030-5602-4FE3-9F00-8A3BBEECFFDEQ47694934-EF988F22-B130-4D2B-B118-3BAB9C2348BBQ47780997-0AF809F9-9465-4795-A29F-A6B9C847C855Q47785792-9FE7A81A-06B7-4343-B605-D2CA1C8EED3DQ47861374-3151FEA3-C5CC-4711-A6C0-725905FF84D7Q47970067-018F5CCB-E837-4B14-9D7A-2A8F6209351DQ49919112-2C54D2D7-F60D-46E6-90A4-ADCE09CECE20Q59128390-C7FD6CCF-CEF3-45DF-A775-0B9D91121B51
P2860
Novel therapeutic targets in depression: minocycline as a candidate treatment.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Novel therapeutic targets in depression: minocycline as a candidate treatment.
@en
type
label
Novel therapeutic targets in depression: minocycline as a candidate treatment.
@en
prefLabel
Novel therapeutic targets in depression: minocycline as a candidate treatment.
@en
P2093
P50
P1476
Novel therapeutic targets in depression: minocycline as a candidate treatment
@en
P2093
Alissa M Powell
Elisa Brietzke
Hanna O Woldeyohannes
Marena S Manierka
Rodrigo B Mansur
Roger S McIntyre
P304
P356
10.1016/J.BBR.2012.07.026
P407
P577
2012-08-10T00:00:00Z